Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 4, Issue 3, Pages 113-119

Therapeutic Options in the Treatment and Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Ulceration

Malcolm C Champion

Division of Gastroenterology, Ottawa Civic Hospital, Ottawa, Ontario, Canada

Copyright © 1990 Canadian Association of Gastroenterology. This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (, which permits reuse, distribution, and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.


This article reviews the current status of H2 receptor antagonists, omeprazole, sucralfate and misoprostol as therapeutic options for the prophylaxis and treatment of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal ulceration. The efficacy of the Hz receptor antagonists appears to be restricted to prophylaxis and treatment of NSAID-induced duodenal ulcer disease. Omeprazole may have a place in the future treatment of NSAID-induced gastric ulcers. However, more studies are necessary to examine this drug's efficacy in both the prophylaxis and treatment of NSAID-induced ulceration. Sucralface improves symptoms, but does not appear to have any effect on improving gastric mucosal damage when compared to placebo. It may, however, be useful in the treatment of NSAID-induced duodenal ulcers. Misoprostol is effective in both the prophylaxis and treatment of NSAID-induced gastric ulcers; however, its exact role in the prophylaxis and treatment of NSAlD-induced duodenal ulcers remains to be defined.